Study at a glance
How was vitamin D studied in bone health and fracture prevention?
This page compares mouse experiments on bone and mineral regulation with a large human trial of vitamin D3 and fractures. The experiments examined how minerals enter bone and how bone cells respond to vitamin D. These processes matter, but changes in them do not automatically prove that supplements prevent broken bones.
What happened to bone health when vitamin D signals changed in mice?
Mice with reduced responses to vitamin D in the intestine absorbed less calcium. Their blood calcium stayed similar to that in control mice while their bones deteriorated. Other experiments linked vitamin D signals in particular bone cells to mineral loss under toxic exposure to calcitriol, the active vitamin D hormone. Changes in cartilage and phosphate-regulating signals also affected developing bone. Some differences disappeared as the mice matured, and dietary changes did not correct every problem.
Did vitamin D supplements reduce fractures in the VITAL trial?
The VITAL analysis included 25,871 adults who were not selected because they had vitamin D deficiency or osteoporosis, a condition that weakens bones. Vitamin D3 at 2,000 international units (IU) daily did not clearly reduce fractures compared with placebo over a median follow-up of 5.3 years. A first fracture occurred in 769 of 12,927 people receiving vitamin D and 782 of 12,944 receiving placebo. Hip-fracture results also showed no clear benefit.
Do these findings apply to people with severe vitamin D deficiency?
Very few measured VITAL participants had severely low vitamin D. The result therefore does not show that treating severe deficiency or osteomalacia, a bone-softening condition, is ineffective. The mouse experiments used genetic changes or toxic active-hormone exposure, which differ from ordinary vitamin D3 supplementation. Together, these studies show neither a universal bone benefit nor universal bone harm. Blood-test changes and bone-cell signals must be distinguished from whether people actually broke bones.
Read the full article below ↓Vitamin D-related signalling affects mineral supply and bone-cell behaviour in experimental models, but those mechanisms do not automatically establish fracture prevention with supplements. The selected studies distinguish mineralisation, remodelling and clinical fractures, preserving the different exposures and populations involved. For the detailed analysis, see Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Full Study.
Intestinal absorption and local signalling both mattered
Lieben’s intestinal-VDR knockout mice maintained serum calcium through compensatory hormonal changes while skeletal mineralisation and cortical integrity deteriorated. Both mineral release and reduced incorporation into bone contributed. A mineral-rich rescue diet altered the phenotype, supporting the importance of supply.
A mature osteoblast/osteocyte VDR-deletion model was largely normal at baseline but protected against high-calcitriol mineralisation impairment. These findings concern particular tissues and conditions, not a universal beneficial or harmful effect of vitamin D in bone. They connect Vitamin D and Calcium with Vitamin D and Calcium Physiology while showing that serum calcium is not a direct measure of skeletal stores.
Cell-lineage experiments separated signalling from resorption
Mori used a toxic active-calcitriol regimen in mice: 5 micrograms/kg daily for four days. Anti-RANKL treatment blocked osteoclast and CTX responses, but only partly prevented calcium and FGF23 effects. Osteoblast-lineage VDR deletion protected against key proresorptive responses.
This supports a specific mechanism linking osteoblast-lineage signalling with osteoclast output. It does not establish harm from ordinary oral vitamin D3. Small groups, high-dose toxicity and the use of earlier evidence in the final schematic limit broader conclusions.
Masuyama’s juvenile cartilage-VDR model altered osteoclast recruitment and osteoblast-associated FGF23, with several skeletal differences normalising by eight weeks. The responsible cartilage-derived factor remained unknown. Developmental recruitment is not interchangeable with adult remodelling or human fracture risk.
Phosphate regulation was essential to the experimental system
Shimada’s global Fgf23 deletion produced high phosphate and calcitriol, abnormal mineralised bone, increased osteoid and early mortality. Partial dietary rescue did not correct everything. Vitamin D and Phosphate Regulation provides the wider relationship, but the model does not prove that calcitriol alone caused every abnormality.
The distinction between active hormone and its precursor, explained in Vitamin D Activation, is essential throughout these experiments. Genetic deletion and toxic calcitriol exposure are not equivalent to nutritional supplementation.
VITAL did not show a fracture reduction in its population
LeBoff’s VITAL analysis included 25,871 adults not selected for deficiency or osteoporosis, comparing 2,000 IU vitamin D3 daily with placebo over a median 5.3 years. First total fractures occurred in 769/12,927 versus 782/12,944 participants: hazard ratio 0.98, 95% confidence interval 0.89 to 1.08, p=.70. Nonvertebral and hip-fracture comparisons were also null.
Mean baseline vitamin D was 30.7 ng/mL, and only 2.4% of measured participants were below 12 ng/mL. Outside supplements were permitted within specified limits. The result does not establish ineffectiveness of treating severe deficiency or osteomalacia.
PTH decreased in a measured subset without an established overall fracture benefit. This is a biochemical response, not proof of fracture mediation. The main text and tables were examined; unavailable graphics and supplements were not used for subgroup claims.
Conclusion
The experimental studies explain specific skeletal mechanisms, while VITAL answers a bounded clinical supplementation question. Neither universal bone benefit nor universal bone harm follows from combining them. Interventions, cell targets, mineral conditions and measured outcomes must remain separate.
Primary source and publication details
LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, Black D, Gallagher JC, Lee IM, Buring JE, Manson JE. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. The New England journal of medicine. 2022;387(4):299-309. DOI 10.1056/nejmoa2202106. PMID 35939577.
Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.
Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.
Mori T, Horibe K, Koide M, Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo. Endocrinology. 2020;161(11):bqaa178. DOI 10.1210/endocr/bqaa178. PMID 32987399.
Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. The Journal of clinical investigation. 2004;113(4):561-568. DOI 10.1172/jci19081. PMID 14966565.
Related reading
The Conundrum of Medical Fracture Prevention in Chronic Kidney Disease: Summary of the Evidence and Pragmatic Clinical Guidance
For teriparatide, the limited evidence in patients with low bone turnover disease is evaluated.
Original paper ↗Read more →The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo
Using osteoblast-lineage-specific VDR conditional knockout (Ob-VDR-cKO) mice, we examined whether proresorptive activity induced by the high-dose 1α,25(OH)2D3 was also mediated by VDR in osteoblast-lineage cells.
Original paper ↗Read more →Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Full Study
Compare bone mineralisation and cell-signalling experiments with VITAL fracture results, keeping doses, models and clinical limits distinct.
Read more →Efficacy of Danshen injection combined with Calcitriol and Calcium/Vitamin-D for the treatment of osteoporotic fractures: A retrospective case-control study
To explore the efficacy of Danshen injection combined with calcitriol and calcium/Vitamin-D in the treatment of osteoporotic fractures.
Original paper ↗Read more →Influence of bone densitometry on the anti-osteoporosis treatment after fragility hip fracture
We examined whether patients had received bone mineral density assessment and received anti-osteoporosis therapy during the period of hospitalization.
Original paper ↗Read more →Short-term anabolic agent and sequential therapy to improve bone mineral density and bone turnover markers in patients with osteoporotic hip fractures
This study aimed to evaluate the effectiveness of sequential therapy using short-term anabolic agents followed by antiresorptive treatment on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with osteoporotic hip fractures.
Original paper ↗Read more →Comparative study on the efficacy of menadione, zoledronic acid, and calcitriol in combination with PKP for the treatment of osteoporotic vertebral compression fractures in extremely elderly patients
Patients with osteoporotic vertebral compression fractures (OVCF) were assigned into 4 groups.
Original paper ↗Read more →Patients with Periprosthetic Femoral Hip Fractures are Commonly Classified as Having Osteoporosis Based on DXA Measurements
Data were compared to two age-, sex-, and BMI-matched control groups in which patients underwent DXA prior to aseptic revision surgery for other causes or primary THA (consisting of 40 patients each).
Original paper ↗Read more →Strategies to overcome barriers to implementing osteoporosis and fracture prevention guidelines in long-term care: a qualitative analysis of action plans suggested by front line staff in Ontario, Canada
The purpose of this study was to identify barriers to the implementation of evidence-based practices for osteoporosis and fracture prevention in LTC facilities and elicit practical strategies to address these barriers.
Original paper ↗Read more →Effect of early preventive supplementation with calcium and phosphorus on metabolic bone disease in premature infants
The objective was to study the effect of early preventive calcium and phosphorus supplementation on metabolic bone disease in preterm infants.
Original paper ↗Read more →Vitamin D and Calcium in Osteoporosis, and the Role of Bone Turnover Markers: A Narrative Review of Recent Data from RCTs
A total of 26 randomized clinical trials (RCTs) were included in this review.
Original paper ↗Read more →A Case Report of Mixed Osteomalacia and Low Bone Density from Vitamin D Deficiency as a Cause of Bilateral Tibial Stress Fractures in a Young Male Military Recruit from Singapore
Despite being a tropical country, vitamin D deficiency is common in Singapore.
Original paper ↗Read more →Association between bone turnover markers, BMD and height loss of cemented vertebrae after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures
The purpose is to explore the risk factors among several potential predictors for the height loss of treated vertebral bodies after PVP in patients with OVCF.
Original paper ↗Read more →Association between phosphorus intake and wrist fracture: the mediating role of bone mineral density
This study aimed to trace phosphorus intake: wrist fracture association, and analyze the mediating role of BMD.
Original paper ↗Read more →Association of bone metabolic markers, bone mineral density and clinical characteristics with the occurrence of secondary fractures after PVP/PKP for osteoporotic thoracolumbar fractures: a study on logistic
A retrospective study was conducted on 107 OTF patients treated in our hospital from May 2023 to May 2024.
Original paper ↗Read more →Beyond Bone Mineral Density: Real-World Fracture Risk Profiles and Therapeutic Gaps in Postmenopausal Osteoporosis
This study aimed to assess the prevalence of osteoporosis and osteopenia, treatment patterns, and skeletal fragility indicators in a large cohort of postmenopausal women undergoing DXA screening.
Original paper ↗Read more →Free vitamin D correlate better with bone mineral density and thoracolumbar junction osteoporotic vertebral fractures than serum vitamin D
Therefore, the aim of the present study is to analyse if free vitamin D correlates with BMD and osteoporotic fragile vertebral fractures in the elderly population.
Original paper ↗Read more →Self-perceived Fracture Risk in the Global Longitudinal Study of Osteoporosis in Women: Its Correlates and Relationship with Bone Microarchitecture
The purpose of this study is to examine correlates of self-perceived fracture risk (SPR) and relationships between SPR and subsequent bone density and microarchitecture in the UK arm of the Global Longitudinal Study of Osteoporosis in Women.
Original paper ↗Read more →The Real‐World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study
Thus, this study aimed to investigate the real‐world effect of 12 months of romosozumab treatment on BMD increase and identify factors that predict the rate of BMD increase after 12 months of romosozumab treatment.
Original paper ↗Read more →Vitamin D receptor gene polymorphisms, bone mineral density and fractures in postmenopausal women with osteoporosis
The study group comprised of 501 postmenopausal females with osteoporosis (mean age 66.4 ± 8.9), who were diagnosed on the basis of either the WHO criteria or self-reported history of low-energy fractures.
Original paper ↗Read more →The essential role of combined calcium and vitamin D supplementation in the osteoporosis scenario in italy: Expert opinion paper
An Italian multidisciplinary working group discussed the current Italian scenario of osteoporosis management during a meeting and highlighted the essential role of calcium and vitamin D supplementation in the prevention of fragility fractures.
Original paper ↗Read more →Original sources
Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults
Published in The New England journal of medicine (2022).
Publication details
LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, Black D, Gallagher JC, Lee IM, Buring JE, Manson JE. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. The New England journal of medicine. 2022;387(4):299-309. DOI 10.1056/nejmoa2202106. PMID 35939577.
Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization
Published in The Journal of clinical investigation (2012).
Publication details
Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.
Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts
Published in The Journal of clinical investigation (2006).
Publication details
Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.
The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo
Using osteoblast-lineage-specific VDR conditional knockout (Ob-VDR-cKO) mice, we examined whether proresorptive activity induced by the high-dose 1α,25(OH)2D3 was also mediated by VDR in osteoblast-lineage cells.
Publication details
Mori T, Horibe K, Koide M, Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo. Endocrinology. 2020;161(11):bqaa178. DOI 10.1210/endocr/bqaa178. PMID 32987399.
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism
Published in The Journal of clinical investigation (2004).
Publication details
Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. The Journal of clinical investigation. 2004;113(4):561-568. DOI 10.1172/jci19081. PMID 14966565.